New Intranasal and Injectable Gene Therapy for Healthy Life Extension
bioRxiv preprint doi: https://doi.org/10.1101/2021.06.26.449305; this version posted June 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. New intranasal and injectable gene therapy for healthy life extension Subtitle: Intranasal and systemic telomerase and follistatin gene therapies to combat an unmet medical need, the effects of biological aging. Dabbu Kumar Jaijyan1*, Anca Selariu2*, Ruth Cruz-Cosme3, Mingming Tong4, Shaomin Yang5, George Church6, David Kekich2, Ali Fallah2, Junichi Sadoshima4, Qiyi Tang3, Elizabeth Parrish2†, Hua Zhu1† Affiliation 1. Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers – New Jersey Medical School, 225 warren street, Newark, New Jersey. 07103, USA. 2. BioViva USA Inc, Delaware, United States. 3. Department of Microbiology, Howard University College of Medicine, 520 W Street NW, Washington DC, 20059, USA. 4. Department of Cell Biology and Molecular Medicine, Rutgers – New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA. 5. Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People's Hospital, The 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China. 6. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. *Co-first authors, these authors contributed equally to this work. † Corresponding authors Abbreviations: CMV, cytomegalovirus; DPI, days post-Inoculation and days post-Infection, FST, follistatin; IVIS, In Vivo Imaging System; MCMV, mouse cytomegalovirus; NCD, Noncommunicable diseases; PFU, plaque-forming-unit; TERT, telomerase reverse transcriptase; WHO, World Health Organization.
[Show full text]